Earnings summaries and quarterly performance for Aprea Therapeutics.
Executive leadership at Aprea Therapeutics.
Board of directors at Aprea Therapeutics.
Research analysts covering Aprea Therapeutics.
Recent press releases and 8-K filings for APRE.
Aprea Therapeutics Announces Private Placement
APRE
New Projects/Investments
- Aprea Therapeutics announced a private placement to sell an aggregate of 6,288,857 shares of common stock (or pre-funded warrants) and warrants to purchase up to 6,288,857 shares of common stock.
- The combined effective offering price for each share and accompanying warrant is $0.89, with the warrants having an exercise price of $0.765 per share.
- The offering is estimated to generate approximately $5.6 million in gross proceeds and is expected to close on or about January 30, 2026.
- The net proceeds from the private placement will be used for general corporate purposes and research and development expenses, including supporting the ACESOT-1 dose-escalation study for APR-1051.
Jan 29, 2026, 9:16 PM
Aprea Therapeutics Announces Early Clinical Proof-of-Concept for APR-1051
APRE
New Projects/Investments
- Aprea Therapeutics announced early clinical proof-of-concept for its WEE1 inhibitor, APR-1051, in the ongoing Phase 1 ACESOT-1051 dose-escalation study.
- The study observed the first unconfirmed partial response (uPR) in an endometrial cancer patient treated with the 150 mg dose, showing a 50% reduction in target lesion size and a significant decrease in CA-125 levels.
- A potential dose-response trend has been observed with increasing single-agent activity across the 70 mg, 100 mg, and 150 mg cohorts, and enrollment is currently underway for the 220 mg dose level.
Jan 29, 2026, 1:27 PM
Aprea Therapeutics Announces Private Placement
APRE
New Projects/Investments
- Aprea Therapeutics has entered into a securities purchase agreement for a private placement to sell 6,288,857 shares of common stock (or pre-funded warrants) and accompanying warrants.
- The combined effective offering price for each share (or pre-funded warrant) and accompanying warrant is $0.89, with warrants exercisable at $0.765 per share.
- The offering is estimated to generate approximately $5.6 million in gross proceeds, which the company intends to use for general corporate purposes and research and development expenses.
- This financing is expected to enable the company to proactively backfill patients in its ongoing ACESOT-1 dose-escalation study for APR-1051, aiming to accelerate dose optimization and define the optimal dose and patient population.
Jan 29, 2026, 1:25 PM
Aprea Therapeutics Updates Corporate Presentation with Clinical Milestones and Financial Position
APRE
New Projects/Investments
Guidance Update
- Aprea Therapeutics, Inc. updated its corporate presentation on January 9, 2026, detailing its precision oncology pipeline focused on synthetic lethality.
- The company's WEE1 inhibitor, APR-1051 (ACESOT-1051), showed encouraging single-agent dose response in its Phase 1 study, with clinical activity observed in colorectal and head and neck cancers at doses starting from 70 mg. Aprea anticipates safety/efficacy data in Q1 2026 and completion of dose escalation in Q2 2026.
- For its ATR inhibitor, ATRN-119 (ABOYA-119), a clinical update was provided in Q4 2025, and the Recommended Phase 2 Dose (RP2D) was determined in October 2025. Further monotherapy enrollment is paused to consider combination approaches.
- Aprea Therapeutics reported cash and equivalents of approximately $13.7 million as of September 30, 2025, and expects to be financed into Q1 2027.
Jan 9, 2026, 9:30 PM
Acrivon Therapeutics Announces Positive Clinical Data Updates and Financial Outlook
APRE
New Projects/Investments
Guidance Update
- Acrivon Therapeutics reported positive interim data from its ACR-368 Phase 2b trial in endometrial cancer, showing a 39% overall response rate (ORR) in BM+ subjects and a 52% confirmed ORR (cORR) in serous subtype subjects with ≤2 prior lines of therapy.
- The company submitted a Phase 3 confirmatory protocol to the FDA for ACR-368, with global trial readiness expected mid-2026, and anticipates completing enrollment for Arm 3 of the Phase 2 trial in Q4 2026 following EU expansion in Q1 2026.
- Initial Phase 1 data for ACR-2316 (WEE1/PKMYT1 inhibitor) showed favorable tolerability and tumor shrinkage in 9 out of 20 evaluable patients, including a confirmed partial response in endometrial cancer. Additionally, ACR-6840 was nominated as the next preclinical development candidate, with IND submission planned for Q4 2026.
- As of December 31, 2025, Acrivon had approximately $119 million in preliminary cash, cash equivalents, and investments, projected to fund operations into the second quarter of 2027.
Jan 8, 2026, 12:30 PM
Aprea Therapeutics CEO Highlights 2025 Progress and 2026 Plans
APRE
Guidance Update
New Projects/Investments
- Aprea Therapeutics' CEO issued a letter on December 18, 2025, highlighting clinical progress and plans for 2026.
- The lead WEE1 inhibitor program, APR-1051, is currently enrolling patients in the 220 mg cohort (Cohort 8) of its dose-escalation study, with observed disease stabilization in several patients and a 15% reduction in tumor burden in one instance. Near-term catalysts include additional safety and efficacy data in Q1 2026 and completion of dose escalation in 2026.
- The ATR inhibitor program, ATRN-119, reached its recommended Phase 2 dose for once-daily dosing, but the company is pausing further enrollment in monotherapy arms to preserve cash and will focus on evaluating combination therapies.
- A $3.1 million (gross) private placement financing was completed, which is projected to extend the company's cash runway into Q1 2027.
Dec 18, 2025, 1:30 PM
Aprea Therapeutics Announces $3.1 Million Private Placement
APRE
- Aprea Therapeutics, Inc. announced a private placement expected to generate approximately $3.1 million in gross proceeds.
- The offering involves the sale of 2,623,023 shares of common stock (or pre-funded warrants) and warrants to purchase up to an aggregate 2,623,023 shares of common stock.
- The combined effective offering price for each share of common stock (or pre-funded warrant) and accompanying warrant is $1.165, with the warrants having an exercise price of $1.04 per share.
- The company intends to use the proceeds for general corporate purposes and research and development expenses, which are expected to extend its cash runway into Q1 2027.
- The private placement is anticipated to close on or about December 10, 2025.
Dec 9, 2025, 9:30 PM
Aprea Therapeutics Announces $3.1 Million Private Placement
APRE
New Projects/Investments
- Aprea Therapeutics, Inc. announced a private placement expected to generate approximately $3.1 million in gross proceeds.
- The offering includes the sale of 2,623,023 shares of common stock (or pre-funded warrants) and warrants to purchase up to 2,623,023 shares of common stock, with a combined effective offering price of $1.165 per unit.
- The company anticipates that the proceeds will extend its cash runway into Q1 2027.
- The private placement is expected to close on or about December 10, 2025.
Dec 9, 2025, 1:30 PM
Aprea Therapeutics Reports Q3 2025 Financial Results and Clinical Updates
APRE
Earnings
Guidance Update
New Projects/Investments
- Aprea Therapeutics reported a net loss of $3.0 million ($0.47 per basic share) for the third quarter ended September 30, 2025, compared to a net loss of $3.8 million ($0.64 per basic share) for the same period in 2024.
- As of September 30, 2025, the company had cash and cash equivalents of $13.7 million, which is projected to fund operations into the fourth quarter of 2026.
- In clinical development, the APR-1051 (WEE1 kinase inhibitor) trial showed 3 out of 4 patients at the 100 mg once daily dose level achieved stable disease, and dose escalation has advanced to the 150 mg once daily cohort.
- For ATRN-119 (ATR kinase inhibitor), the recommended Phase 2 dose (RP2D) of 1,100 mg once daily was identified, and further monotherapy enrollment is paused to consider combination strategies.
Nov 12, 2025, 1:35 PM
Aprea Therapeutics Provides Clinical Update on ACESOT-1051 Trial
APRE
New Projects/Investments
- Aprea Therapeutics, Inc. provided a clinical update from the ACESOT-1051 trial for its WEE1 Kinase Inhibitor APR-1051, showing early signals of activity.
- At the 100 mg APR-1051 dose level, 3 out of 4 patients achieved stable disease (per RECIST v1.1) in heavily pretreated gastrointestinal and gynecologic malignancies.
- Disease stabilization was observed in patients with tumors harboring FBXW7, CCNE1, KRAS G12V, and TP53 mutations, which are relevant to WEE1 kinase inhibition.
- The trial has progressed to Dose Level 7 (150 mg), with no dose-limiting toxicities or unexpected safety issues reported to date.
Oct 24, 2025, 12:35 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more